In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hexagen PLC

Division of Incyte Corp.

Latest From Hexagen PLC

Is Product Infatuation the Death Knell for Platforms?

Incyte Genomics Inc., the creator of the database model and practically the ur-platform company, has suddenly decided to turn into a drug discovery company--changing top management to do so. Other firms that decided years ago to leverage genetic information to create drugs have far higher valuations than Incyte--indeed biotechs reporting product revenues get valuation multiples on sales that are twice as high as those platform companies command --and about triple the multiples that Big Pharma receives on its sales.
BioPharmaceutical Strategy

Transactions 1999: Dealmaking for the New Economy

The number of early-stage deals plummeted as large drug companies fought their way through mergers and other late-stage deals designed to boost near-term earnings. Drug companies also looked to mergers to build up sales forces and, by building bigger-selling products, to compensate for the lack of R&D productivity. Meanwhile, biotechs, with valuations at record levels, looked to find deals that would allow them to keep the upside of their products and move their share prices up.
BioPharmaceutical Medical Device

Big Foot: Celera Steps into the Genomic Market

PE Corp. created Celera to exploit its high-productivity new sequencer, the Prism 3700, and build a broad set of proprietary genomic databases. The move instantly boosted sales of the new sequencer, paying for the expensive start-up in increased revenues to PE's PE Biosystems division and a dramatic increase in market value. Unlike its genomic database competitors, Celera won't charge subscribers royalties and milestones for successful use of the data. To encourage broad and continuing use of the system it hopes will become the industry standard, it plans to make money largely on subscription fees and enlarging its client base, not reach-through rights. But novel genetic data is just the hook for catching clients--Celera hopes to keep them subscribing with a program of continuous annotations and a set of bioinformatics tools that enable a level of in silico experimentation once requiring highly expensive in vitro and in vivo studies. But a raft of new and older competitors stand in the way of its bioinformatics ambitions.
BioPharmaceutical Strategy

Kiva Genetics Inc. (Now DNA Sciences Inc.)

While gene sequencing and gene expression technologies have become relatively industrialized, genetic analysis is a time-consuming, labor intensive, and rate-limiting step in drug discovery. Kiva Genetics hopes to remove this bottleneck with a high-throughput system that miniaturizes and automates genotyping.
BioPharmaceutical Platform Technologies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Incyte Corp.
  • Senior Management
  • Contact Info
  • Hexagen PLC
    Phone: (44) 12234248
    214 Cambridge Science Park
    Milton Rd.
    Cambridge, CB4 4WA